上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。
IP2
IP2 是一种免疫调节剂。IP2 增加癌细胞中 PTP 衍生的抗原呈递。IP2 对癌细胞无细胞毒性。IP2 在小鼠体内诱导肿瘤生长缺陷。
| 规格 |
|
是否有货 |
|
| 100 mg |
|
询价 |
|
| 250 mg |
|
询价 |
|
| 500 mg |
|
询价 |
|
* Please select Quantity before adding items.
| 生物活性 |
IP2 is an immunomodulatory agent. IP2 increases PTP (Pioneer Translation Product)-derived antigen presentation in cancer cells. IP2 shows non-cytotoxic for cancer cells. IP2 induces tumor growth defects in mouse[1].
|
体外研究
(In Vitro) |
IP2 (35 µM) shows immunomodulatory activity in murine MCA205 fibrosarcoma cells[1].
IP2 (35 µM) increases in the intron-derived SL8 antigen presentation[1].
IP2 (10 µM; 72 h) shows non-cytotoxic for cancer cells[1].
IP2 (10 µM) shows selectivity against three G-protein coupled receptor ADRB1 (35%), HRH2 (40%), and OPRD1 (53%), and inhibits the three enzymes of COX1 (52.8%), PDE3A (84.8%), and PDE4D2 (87.2%)[1].
IP2 (10 µM) dose not induce immunogenic cell death hallmarks in human osteosarcoma U2OS cells[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
| Cell Line: |
MCF-7, A549, HCT116, K562, MCA205, B16F10, K562R, HUVEC cells |
| Concentration: |
10 µM |
| Incubation Time: |
72 h |
| Result: |
Showed non-cytotoxic for cancer cells. |
|
体内研究
(In Vivo) |
IP2 (0.711 mg/kg for i.p. for mice; 9.103 mg/kg for i.v. for nice; 26.76 mg/kg for i.v. for dog) shows a high bioavailability in mice[1].
IP2 (50, 100, 250, 500 mg/kg; i.p.) shows very well toleration in C57BL/6 mice[1].
IP2 (2.5 mg/kg; i.v.) induces tumor growth defects in C57BL/6 mice[1].
IP2 (5 mg/kg; intratumor injection; three times per week for 2 weeks) induces tumor growth defects in C57BL/6 mice[1].
Pharmacokinetic Parameters of IP2 in Male C57BL/6J mice and male beagle dog[1].
|
Dose (mg/kg) |
Cmax (ng/mL) |
Tmax (h) |
T1/2 (h) |
CL (mL/min/kg) |
F % |
MRT0-t (h) |
AUCtot (ng/mL·h) |
AUCextra (%) |
| ip mice |
9.103 |
2078 |
0.0833 |
0.8 |
154 |
86 |
0.7 |
982.3 |
1.3 |
| iv mice |
0.711 |
322.7 |
0.0833 |
1.1 |
133 |
|
0.9 |
88.8 |
15.2 |
| iv dog |
26.76 |
272 (µg/mL) |
0.0833 |
3.8 |
0.69 |
|
3.8 |
654.7 (µg/mL·h) |
0.9 |
Male C57BL/6J mice and male beagle dog; 0.711 mg/kg for i.p. for mice; 9.103 mg/kg for i.v. for mice; 26.76 mg/kg for i.v. for dog[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: |
Male C57BL/6J mice and male beagle dog[1] |
| Dosage: |
0.711 mg/kg for i.p. for mice; 9.103 mg/kg for i.v. for nice; 26.76 mg/kg for i.v. for dog |
| Administration: |
I.p. or i.v. |
| Result: |
Exhibited a high bioavailability in mice and a very low clearance in dogs and a moderate half-life of elimination. |
| Animal Model: |
Female C57BL/6 mice[1] |
| Dosage: |
50, 100, 250, 500 mg/kg |
| Administration: |
I.p. |
| Result: |
Showed very well toleration in C57BL/6 mice. |
| Animal Model: |
C57BL/6 mice[1] |
| Dosage: |
5 mg/kg |
| Administration: |
Intratumor injection; three times per week for 2 weeks |
| Result: |
Shows a 50% decreased in MCA205 WT fibrosarcoma growth at killing. |
|
| 分子量 |
|
| Formula |
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Please store the product under the recommended conditions in the Certificate of Analysis.
|
| 参考文献 |
|
所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务
